Xiu-tao Fu
Zhongshan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma.
Journal: Journal for immunotherapy of cancer
Published: June 24, 2026
Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma.
Journal: Experimental hematology & oncology
Published: July 23, 2025
Application of targeted deep sequencing for management of hepatocellular carcinoma in a real-world setting: prediction of MRD and adjuvant lenvatinib response.
Journal: Cancer letters
Published: July 16, 2025
Predictive value of neutrophil-to-lymphocyte ratio in recurrent HCC after repeat hepatectomy or salvage liver transplantation.
Journal: Hepatology international
Published: December 04, 2024
Inhibition of SIRT1 relieves hepatocarcinogenesis via alleviating autophagy and inflammation.
Journal: International journal of biological macromolecules
Published: April 22, 2024
Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer.
Journal: Hepatology international
Published: April 26, 2023
Autophagy suppression facilitates macrophage M2 polarization via increased instability of NF-κB pathway in hepatocellular carcinoma.
Journal: International immunopharmacology
Published: February 10, 2023
Inhibition of autophagy in macrophage promotes IL-1β-mediated hepatocellular carcinoma progression via inflammasome accumulation and self-recruitment.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 08, 2023
Single-cell and spatial architecture of primary liver cancer.
Journal: Communications biology
Published: September 25, 2022
Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges.
Journal: Journal of oncology
Published: July 31, 2022
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.
Journal: BJS open
Published: May 19, 2022
Last Updated: 09/26/2026